MGI Pharma held by Bear Stearns at outperform

MGI Pharma Inc. was kept by Bear Stearns analyst Vinay Thapar at an outperform rating with a price target of $33 per share following the company's second quarter earnings. Bloomington, Minn.-based MGI Pharma develops treatments for cancer patients, such as chemotherapy-induced nausea and dry mouth. MGI Pharma shares Thursday added $1.46, or 6.06%, to $25.56 on volume of 3.47 million shares versus the three-month running average of 1.18 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.